公开(公告)号：US20220185885A1

公开(公告)日：2022-06-16

申请号：US17601354

申请日：2020-04-03

Applicant: ONO PHARMACEUTICAL CO., LTD.

Inventor： Shiro SHIBAYAMA ,  Tomoya TEZUKA ,  Mark THROSBY ,  Cornelis Adriaan DE KRUIF ,  Pieter Fokko VAN LOO ,  Rinse KLOOSTER ,  Robertus Cornelis ROOVERS

IPC: C07K16/28

Abstract: An agent for preventing, suppressing the progression of symptoms of, suppressing the recurrence of or treating autoimmune diseases, comprising a bispecific antibody or an antibody fragment thereof, having a first arm specifically binding to PD-1 and a second arm specifically binding to CD19, as described herein.

公开(公告)号：US20220281977A1

公开(公告)日：2022-09-08

申请号：US17630426

申请日：2020-07-29

Applicant: ONO PHARMACEUTICAL CO., LTD.

Inventor： Shiro SHIBAYAMA ,  Takuya SHIMBO ,  Tomoya TEZUKA ,  Mark THROSBY ,  Cornelis Adriaan DE KRUIF ,  Pieter Fokko VAN LOO ,  Rinse KLOOSTER

IPC: C07K16/28 ,  C07K16/46 ,  A61P37/02

Abstract: A PD-1/CD3 bispecific antibody or an antigen-binding fragment thereof useful for preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases is disclosed. The PD-1/CD3 bispecific antibody comprises a first arm specifically binding to PD-1 and a second arm specifically binding to CD3. The PD-1/CD3 bispecific antibody can be formulated into a formulation which can reduce the occurrence of adverse reactions called as infusion reaction or cytokine release syndrome and the bispecific antibody contributes to enhancement or duration of an effect of preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases.